Quick Answer
Protagonist Therapeutics, Inc reported Net Income Loss of -$130.15 million for the year ending 2025.
- Protagonist Therapeutics, Inc showed a decrease of -147.3% in Net Income Loss from 2024 to 2025.
- This data is from Protagonist Therapeutics, Inc's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Protagonist Therapeutics, Inc's Net Income Loss has declined by 1,075.5%.
- Historical annual values: Fiscal year 2025: -$130.15 million | Fiscal year 2024: $275.19 million | Fiscal year 2023: -$78.96 million | Fiscal year 2022: -$127.39 million | Fiscal year 2021: -$125.55 million | Fiscal year 2020: -$66.15 million | Fiscal year 2019: -$77.19 million | Fiscal year 2018: -$38.92 million | Fiscal year 2017: -$36.96 million | Fiscal year 2016: -$37.18 million | Fiscal year 2015: -$14.86 million | Fiscal year 2014: -$11.07 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: